KLSC Urges Caution on Proposed COINS Act Restrictions to Protect Access to Innovative Medicines
KLSC supports the Administration’s efforts to protect national security and strengthen America's global competitiveness. However, the proposed expansion of the COINS Act to include restrictions on U.S. investment in China's biotechnology sector risks unintended consequences for medical progress and patient access to new therapies.
New Report Highlights Continued Growth of Kentucky's Bioscience Industry and Its Impact on Innovation and the Economy
Kentucky's bioscience industry continues to strengthen its role as a major economic driver for the Commonwealth, according to a new report from the Biotechnology Innovation Organization (BIO) and TEConomy Partners. The report found that Kentucky's bioscience workforce grew by 6.9 percent between 2021 and 2025, reaching 17,675 jobs across the state and keeping pace with national growth.
An Open Letter to Congress: Protect Innovation
Medical innovation is changing what is possible for patients facing cancer, rare diseases, and other serious health conditions.
KLSC Statement: President Trump’s Visit to Kentucky
Kentucky Life Sciences Council (KLSC) appreciates this administration visiting Ohio and Kentucky to highlight the efforts our region is making in biopharmaceutical innovation.
OpEd: Keep American biopharma innovation American — fix what’s actually broken in drug pricing
The American economy has been built on innovation and a spirit of making things better. That is especially true for the biopharmaceutical sector, where the United States has long led the way in developing lifesaving cures and medications.
KLSC Commends the Passage of key PBM reforms by Congress
The Kentucky Life Sciences Council applauds the House and Senate for passing long‑overdue pharmacy benefit manager (PBM) reforms, an important step toward curbing the opaque and anticompetitive practices of healthcare middlemen whose profit‑driven models have burdened patients, employers, and taxpayers for far too long.
KLSC released the following statement in support of the inclusion of critical PBM reforms in the Consolidated Appropriations Act, 2026:
KLSC urges Congress to advance the government funding package containing practical PBM reforms that address the affordability crisis fueled by the unfair and profit‑driven practices of healthcare middlemen.
KLSC Christmas List: Unwrapping Reforms for Better Care
As we celebrate the holiday season, KLSC is making its list and checking it twice...and every ask represents a critical step toward better care and innovation. Now it’s up to Congress to deliver these legislative gifts that will bring real cheer to patients and providers. The groundwork has been laid, the momentum is strong, and it’s time to push these measures across the finish line.
KLSC released statement in support of the PBM Price Transparency and Accountability Act
The Kentucky Life Sciences Council commends Senators Mike Crapo (R-ID) and Ron Wyden (D-OR) for their leadership in advancing federal PBM reform with the introduction of the PBM Price Transparency and Accountability Act.
New Report Shows Double-Digit Job Growth for Kentucky’s Bioscience Industry
The bioscience industry footprint is growing in Kentucky, as a new report shows the bioscience workforce in the Commonwealth employs 17,341 people, an increase of 11 percent over the past 5 years.
Op-Ed: Drug pricing reform should be about saving lives through innovation
Around the world, millions of patients, suffering from cancer, Alzheimer’s, cystic fibrosis, and many other chronic diseases, are holding onto hope that one day soon there will be a cure—and America’s biopharmaceutical companies are dedicated to turning these hopes into reality.